

**Supplemental Table.** Baseline characteristics in angiotensin II (ATII) vs. non-angiotensin II (Non-ATII) patients, before (unweighted) and after propensity score weighting (weighted).

<b>Patient Characteristic</b>	<b>Unweighted</b>				<b>Weighted</b>	
	<b>ATII (n=56)</b>	<b>Non-ATII (n=91)</b>	<b>Diff</b>	<b>p</b>	<b>ATII</b>	<b>Non-ATII</b>
Age, $\bar{x} \pm sd$ , years	59.5 $\pm$ 14.9	62.7 $\pm$ 15.7	-0.21	.22	58.7	58.7
Male, no (%)	35 (62.5)	53 (58.2)	4.3%	.61	59.5%	59.5%
BMI, $\bar{x} \pm sd$ , kg/m <sup>2</sup> *	31.7 $\pm$ 10.1	28.2 $\pm$ 7.4	0.40	.03	30.1	30.1
<u>Comorbidities</u>						
Diabetes, no (%)	21 (37.5)	41 (45.1)	-7.6%	.37	29.9%	29.9%
Hypertension, no (%)	23 (41.1)	59 (64.8)	-23.7%	<.01	49.0%	49.0%
Coronary artery disease, no (%)	8 (14.3)	27 (29.7)	-15.4%	.03	19.7%	19.7%
Heart Failure, no (%)	11 (19.6)	39 (42.9)	-23.3%	<.01	27.8%	27.8%
Malignancy, no (%)	15 (26.8)	24 (26.4)	0.4%	.96	23.4%	23.4%
COPD, no (%)	6 (10.7)	11 (12.1)	-1.4%	.80	9.5%	9.5%
Cirrhosis, no (%)	18 (32.1)	20 (22.0)	10.1%	.17	30.2%	30.2%
CVA, no (%)	5 (8.9)	16 (17.6)	-8.7%	.15	11.0%	11.0%
ESRD, no (%)	11 (19.6)	19 (20.9)	-1.3%	.86	17.7%	17.7%
Immunocompromised, no (%)	8 (14.3)	14 (15.4)	-1.1%	.86	16.6%	16.6%
Recent ACE-I/ARB, no (%)	12 (21.4)	22 (24.2)	-2.8%	.70	23.8%	23.8%
Sepsis as etiology of shock, no (%)	55 (98.2)	82 (90.1)	8.1%	.06	96.7%	96.7%

<u>Source of Infection for Septic Shock</u>						
Respiratory, no (%)	31 (55.4)	47 (51.6)	3.8%	.66	53.3%	53.3%
Urinary tract, no (%)	9 (16.1)	15 (16.5)	-0.4%	.95	18.2%	18.2%
Abdominal, no (%)	19 (33.9)	27 (29.7)	4.2%	.59	35.0%	35.0%
Soft tissue, no (%)	5 (8.9)	7 (7.7)	1.2%	.79	7.9%	7.9%
CNS, no (%)	1 (1.8)	2 (2.2)	-0.4%	.86	2.3%	2.3%
Other, no (%)	4 (7.1)	9 (9.9)	-2.8%	.57	6.0%	6.0%
<u>Hemodynamics</u>						
Initial MAP, $\bar{x} \pm sd$ , mmHg	$56.1 \pm 11.1$	$59.7 \pm 14.8$	-0.27	.09	57.9	57.9
Initial Heart Rate, $\bar{x} \pm sd$ , BPM	$103.6 \pm 22.3$	$99.1 \pm 24.8$	0.19	.25	101.0	101.0
<u>Laboratory Values</u>						
WBC, $\bar{x} \pm sd$ , bil/L	$19.9 \pm 14.7$	$13.9 \pm 9.9$	0.49	.01	16.7	16.7
Hemoglobin, $\bar{x} \pm sd$ , g/dL	$9 \pm 2.2$	$9.7 \pm 2.9$	-0.25	.11	9.4	9.4
Platelets, $\bar{x} \pm sd$ , bil/L	$135.7 \pm 100.6$	$141 \pm 86.8$	-0.05	.76	134.6	134.6
Bicarbonate, $\bar{x} \pm sd$ , mMol/L	$15.4 \pm 5.5$	$16.2 \pm 6.6$	-0.13	.43	15.9	15.9
Creatinine, $\bar{x} \pm sd$ , mg/dL	$2.8 \pm 1.7$	$3.2 \pm 2.6$	-0.19	.21	2.7	2.7
Glucose, $\bar{x} \pm sd$ , mg/dL	$137 \pm 94.6$	$174.2 \pm 110.7$	-0.35	.03	145.4	145.4
Total Bilirubin, $\bar{x} \pm sd$ , mg/dL	$7.6 \pm 9.7$	$5.2 \pm 8.1$	0.28	.12	6.8	6.8
Albumin, $\bar{x} \pm sd$ , g/dL	$2.5 \pm 0.8$	$2.5 \pm 0.8$	-0.03	.84	2.5	2.5
INR $\bar{x} \pm sd$ *	$3.0 \pm 1.9$	$2.3 \pm 1.2$	0.44	.02	2.5	2.5
pH $\bar{x} \pm sd$ *	$7.2 \pm 0.1$	$7.6 \pm 3.1$	-0.14	.28	7.2	7.2
Lactate, $\bar{x} \pm sd$ , mMol/L*	$9.1 \pm 7.0$	$7.4 \pm 5.6$	0.27	.13	8.0	8.0
PaO <sub>2</sub> , $\bar{x} \pm sd$ , mmHg*	$129.8 \pm 77.9$	$119.7 \pm 66.9$	0.14	.43	127.8	127.8
FiO <sub>2</sub> , $\bar{x} \pm sd$	$0.8 \pm 0.2$	$0.8 \pm 0.3$	0.04	.80	0.8	0.8
GCS $\bar{x} \pm sd$ *	$7.4 \pm 4.4$	$7.8 \pm 4.5$	-0.07	.67	7.2	7.2
SOFA score, $\bar{x} \pm sd$ *	$15.8 \pm 3.3$	$15.3 \pm 3$	0.18	.30	15.4	15.4
DVT prophylaxis, no (%)	29 (51.8)	56 (61.5)	-9.7%	.24	56.4%	56.4%
Time to vasopressor, $\bar{x} \pm sd$ , hours	$116.3 \pm 172.1$	$252.7 \pm 1060.8$	-0.16	.23	126.0	126.0
Urine output, $\bar{x} \pm sd$ , mL in 24 hours*	$382.8 \pm 825.7$	$345.7 \pm 800.7$	0.05	.79	330.3	330.3

30 ml/kg fluid received prior to initiation of first vasopressor, no (%)*	34 (60.7)	40 (44.4)	16.3%	.06	54.5%	54.5%
Antibiotics, no (%)*	56 (100)	89 (98.9)	1.1%	.43	100%	100%
Steroids, no (%)*	38 (67.9)	44 (48.9)	19.0%	.02	61.0%	61.0%

BMI – body mass index; COPD – chronic obstructive pulmonary disease; CVA – cerebral vascular accident; ESRD – end-stage renal disease; ACE-I – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; CNS – central nervous system; MAP – mean arterial pressure; INR – international normalized ratio; GCS – Glasgow Coma Scale; SOFA – Sequential Organ Failure Assessment; DVT – deep venous thrombosis;

Diff – standardized mean difference for continuous variable and % difference for categorical variable.

\*Denotes variable with missing data for at least one patient.